| Dr Klaus Dittmar, MD | |
|
1999 Marcus Ave Ste 306, New Hyde Park, NY 11042-1028 | |
| (516) 627-1221 | |
| (516) 627-6857 |
| Full Name | Dr Klaus Dittmar |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 67 Years |
| Location | 1999 Marcus Ave Ste 306, New Hyde Park, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245239664 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 089981 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York University Langone Medical Center | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New York University | 1355232422 | 4431 |
News Archive
Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.
Politico reports that while Republican governors in Texas and Louisiana remain firmly in the no camp, others in Pennsylvania, Tennessee, Indiana and Oklahoma are giving the program a second look. News outlets also offer updates from Florida, Pennsylvania, Kansas and Georgia.
Former Vice President Joe Biden secured the 270 electoral votes needed to capture the White House on Saturday, major news organizations projected, after election officials in a handful of swing states spent days in round-the-clock counting of millions of mail-in ballots and early votes.
Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse.
› Verified 2 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20081202000185 |
News Archive
Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.
Politico reports that while Republican governors in Texas and Louisiana remain firmly in the no camp, others in Pennsylvania, Tennessee, Indiana and Oklahoma are giving the program a second look. News outlets also offer updates from Florida, Pennsylvania, Kansas and Georgia.
Former Vice President Joe Biden secured the 270 electoral votes needed to capture the White House on Saturday, major news organizations projected, after election officials in a handful of swing states spent days in round-the-clock counting of millions of mail-in ballots and early votes.
Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse.
› Verified 2 days ago
| Entity Name | North Shore Hematology Oncology,pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407991144 PECOS PAC ID: 2163314808 Enrollment ID: O20081223000406 |
News Archive
Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.
Politico reports that while Republican governors in Texas and Louisiana remain firmly in the no camp, others in Pennsylvania, Tennessee, Indiana and Oklahoma are giving the program a second look. News outlets also offer updates from Florida, Pennsylvania, Kansas and Georgia.
Former Vice President Joe Biden secured the 270 electoral votes needed to capture the White House on Saturday, major news organizations projected, after election officials in a handful of swing states spent days in round-the-clock counting of millions of mail-in ballots and early votes.
Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse.
› Verified 2 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.
Politico reports that while Republican governors in Texas and Louisiana remain firmly in the no camp, others in Pennsylvania, Tennessee, Indiana and Oklahoma are giving the program a second look. News outlets also offer updates from Florida, Pennsylvania, Kansas and Georgia.
Former Vice President Joe Biden secured the 270 electoral votes needed to capture the White House on Saturday, major news organizations projected, after election officials in a handful of swing states spent days in round-the-clock counting of millions of mail-in ballots and early votes.
Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Klaus Dittmar, MD 1999 Marcus Ave Ste 306, New Hyde Park, NY 11042-1028 Ph: (516) 627-1221 | Dr Klaus Dittmar, MD 1999 Marcus Ave Ste 306, New Hyde Park, NY 11042-1028 Ph: (516) 627-1221 |
News Archive
Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.
Politico reports that while Republican governors in Texas and Louisiana remain firmly in the no camp, others in Pennsylvania, Tennessee, Indiana and Oklahoma are giving the program a second look. News outlets also offer updates from Florida, Pennsylvania, Kansas and Georgia.
Former Vice President Joe Biden secured the 270 electoral votes needed to capture the White House on Saturday, major news organizations projected, after election officials in a handful of swing states spent days in round-the-clock counting of millions of mail-in ballots and early votes.
Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse.
› Verified 2 days ago
Dr. Farheen Hasan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 27005 76th Ave, New Hyde Park, NY 11040 Phone: 718-470-7000 | |
Carylann Hadjiyane, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1991 Marcus Ave, Suite 101, New Hyde Park, NY 11042 Phone: 516-365-4949 Fax: 516-365-5462 | |
Paul S. Berg, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2001 Marcus Ave, Suite N204, New Hyde Park, NY 11042 Phone: 516-684-9229 Fax: 516-977-8589 | |
Dr. Michael Jason Levine, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1999 Marcus Ave Ste 220, New Hyde Park, NY 11042 Phone: 516-869-5400 Fax: 516-869-5800 | |
Gisele Wolf-klein, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 2800 Marcus Ave, Suite 200, New Hyde Park, NY 11042 Phone: 516-708-2522 Fax: 516-708-2570 | |
Dr. Monty Max Bodenheimer, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 3003 New Hyde Park Rd, Ste 406, New Hyde Park, NY 11042 Phone: 516-719-0102 Fax: 516-358-5403 | |
Michael Xin Chen, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 27005 76th Ave, New Hyde Park, NY 11040 Phone: 718-470-3377 |